Abstract

Objectives To investigate the safety of live attenuated varicella zoster vaccination when administered to immunosuppressed individuals. Design Prospective observational cohort study. Setting The study used anonymised data from the Clinical Practice Research Datalink (CPRD), comprising a representative sample of routinely collected primary care data in England between 2013 and 2017 and and linked Hospital Episode Statistics data. Participants 168 767 individuals age-eligible for varicella zoster vaccination registered at a general practice in England contributing data to CPRD. Main outcome measures Electronic health records indicating immunosuppression, zoster vaccination, diagnoses of specific varicella-zoster virus (VZV)-related disease and non-specific rash/encephalitis compatible with VZV-related disease. Results Between 1 September 2013 and 31 August 2017, a period of immunosuppression was identified for 9093/168 767 (5.4%; 95% CI: 5.3%–5.5%) individuals age-eligible for zoster vaccination. The overall rate of vaccination while immunosuppressed was 1742/5251 (33.2 per 100 adjusted person years at risk; 95% CI: 31.9%–34.5%). Follow-up of the 1742 individuals who were inadvertently vaccinated while immunosuppressed identified only two cases of VZV-related disease within 8 weeks of vaccination (0.1%; 95% CI: 0.01%–0.4%), both primary care diagnoses of ‘shingles’, neither with a related hospital admission. Conclusions Despite evidence of inadvertent vaccination of immunosuppressed individuals with live zoster vaccination, there is a lack of evidence of severe consequences including hospitalisation. This should reassure primary care staff and encourage vaccination of mildly immunosuppressed individuals who do not meet current thresholds for contraindication. These findings support a review of the extent to which live zoster vaccination is contraindicated among the immunosuppressed.

Keywords

MedicineObservational studyCohort studyAdministration (probate law)CohortVaccine safetyEpidemiologyFamily medicineImmunologyInternal medicineImmunizationImmune system

Affiliated Institutions

Related Publications

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

Publication Info

Year
2020
Type
article
Volume
10
Issue
1
Pages
e034886-e034886
Citations
13
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

13
OpenAlex

Cite This

Daniel Grint, Helen McDonald, Jemma Walker et al. (2020). Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. BMJ Open , 10 (1) , e034886-e034886. https://doi.org/10.1136/bmjopen-2019-034886

Identifiers

DOI
10.1136/bmjopen-2019-034886